Azetukalner
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Azetukalner
- Molecular weight
- 368.5
- Structure (SMILES)
- Cc1cc(N2CCc3cc(F)ccc3C2)cc(C)c1NC(=O)CC(C)(C)C
- azetukalner
- Azetukalner
- azetukalner [INN]
- AZETUKALNER [USAN]
- azetukalner inn
- azetukalner usan
- encukalner
- Encukalner
- xen 1101
- XEN-1101
- xen1101
- XEN1101
- xen1101 10 mg
- XEN1101 10 mg
- xen1101 20 mg
- XEN1101 20 mg
- CAS registry numbers
- 1009344-33-5
- ChEMBL ID
- CHEMBL5095264
- InChIKey
- FJNPZKZPWVVSON-UHFFFAOYSA-N
- PubChem compound IDs
- 24743936
- FDA ingredient codes (UNII)
- 91WL7OD122
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- azetukalner
- Type
- Synthetic organic
- Drug name stem
- -kalner
- Action
- Activation
- Action type
- ACTIVATION
- Target
- Kv7.3
- Gene symbol
- KCNQ3
- Protein identifier
- O43525
- Action
- Activation
- Action type
- ACTIVATION
- Target
- Kv7.2
- Gene symbol
- KCNQ2
- Protein identifier
- O43526
- Condition
- Epilepsies, Partial
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004263
- Subject identifier
- D004828
- Condition
- Seizures
- Highest recorded phase
- 3
- Condition identifier
- HP:0001250
- Subject identifier
- D012640
- Condition
- Epilepsy, Tonic-Clonic
- Highest recorded phase
- 3
- Condition identifier
- HP:0002069
- Subject identifier
- D004830
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition
- Depression
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002050
- Subject identifier
- D003863
- Condition identifier
- EFO_0000474
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004263
- Highest recorded phase
- 3
- Condition identifier
- HP_0001250
- Condition identifier
- HP_0001250
- Highest recorded phase
- 3
- Condition identifier
- HP_0002069
- Highest recorded phase
- 3
- Condition identifier
- HP_0007359
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002050
- Condition identifier
- MONDO_0004985
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005027
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005384
- Highest recorded phase
- 2
- NCT03796962
- NCT04827901
- NCT05376150
- NCT05614063
- NCT05716100
- NCT05667142
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 1
- Polar surface area
- 32.34
- Calculated partition coefficient (ALogP)
- 5.38
- Calculated partition coefficient (XLogP)
- 5.2
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 3
- Heavy atoms
- 27
- Molecular formula
- C23H29FN2O
- Monoisotopic mass
- 368.22639171
- Natural product
- No
- Recorded assays
- 1
- Active assays
- 1
Active assay types
- Confirmatory
Related records
Trials (13)
- A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
- A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
- An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
- An Open-Label Study of Azetukalner in Major Depressive Disorder
- An Open-label Study of XEN1101 in Epilepsy
- Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101
- XEN1101 for Major Depressive Disorder
In development for (7)
- Bipolar disorder Phase 3
- Depressive disorder Phase 1
- Epilepsy Phase 1
- Epilepsy with generalized tonic-clonic seizures Phase 3
- Focal epilepsy Phase 2
- Major depressive disorder Phase 2
- Visual epilepsy Phase 3